These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37248148)

  • 1. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.
    Swami U; Aggarwal H; Zhou M; Jiang S; Kim J; Li W; Laliberté F; Emond B; Agarwal N
    Clin Genitourin Cancer; 2023 Oct; 21(5):517-529. PubMed ID: 37248148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
    Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
    Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
    Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
    Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States.
    Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George DJ
    J Manag Care Spec Pharm; 2024 Jul; 30(7):684-697. PubMed ID: 38950154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
    Shao C; He J; Kachroo S; Jin F
    Cancer Med; 2019 Dec; 8(18):7613-7622. PubMed ID: 31668011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation.
    Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Urosevic A; Lefebvre P; Pilon D; George DJ
    J Med Econ; 2024; 27(1):201-214. PubMed ID: 38204397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.
    Poon DMC; Wong KCW; Chan TW; Law K; Chan K; Lee EKC; Lee C; Chan M;
    Clin Genitourin Cancer; 2018 Oct; 16(5):402-412.e1. PubMed ID: 30126765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
    Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
    Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
    Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
    Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of care and health care resource use among Medicaid-enrolled women with recurrent or metastatic cervical cancer.
    Leath CA; Nysenbaum J; Ting J; Zhang YJ; Fiori A; Pauly N
    J Manag Care Spec Pharm; 2023 May; 29(5):490-498. PubMed ID: 37121257
    [No Abstract]   [Full Text] [Related]  

  • 12. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors.
    Shore ND; Laliberté F; Ionescu-Ittu R; Yang L; Mahendran M; Lejeune D; Yu LH; Burgents J; Duh MS; Ghate SR
    Adv Ther; 2021 Aug; 38(8):4520-4540. PubMed ID: 34282527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
    Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
    Armstrong A; Bui C; Fitch K; Sawhney TG; Brown B; Flanders S; Balk M; Deangelis J; Chambers J
    Curr Med Res Opin; 2017 Jun; 33(6):1133-1139. PubMed ID: 28318331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
    Ryan CJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Freedland SJ
    J Urol; 2021 Dec; 206(6):1420-1429. PubMed ID: 34293915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
    Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
    J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population.
    Freedland SJ; Davis M; Epstein AJ; Arondekar B; Ivanova JI
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):327-333. PubMed ID: 37783836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost impact of disease progression to metastatic castration-sensitive prostate cancer.
    Trinh QD; Chaves LP; Feng Q; Zhu J; Sandin R; Abbott T
    J Manag Care Spec Pharm; 2022 May; 28(5):544-554. PubMed ID: 35471070
    [No Abstract]   [Full Text] [Related]  

  • 20. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
    Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
    JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.